YonedaLabs is a technology company.
YonedaLabs has raised $4.0M across 1 funding round.
YonedaLabs has raised $4.0M in total across 1 funding round.
Yoneda Labs is a San Francisco-based startup founded in 2023 that builds AI-powered software to optimize chemical reactions for the chemical and pharmaceutical industries.[1][2][4] The product, including an app called Yoneda Optimize, learns from chemists' experimental data to recommend optimal parameters like temperature, concentration, and catalysts, reducing optimization time from weeks or months to days while running fully offline for data security.[1][4][6] It serves chemists in drug development and materials synthesis, solving the problem of unreliable literature data and manual trial-and-error by enabling faster, cheaper, and more environmentally friendly synthesis of over 10 million annual compounds.[1][4] The company has raised $4.5M in Seed VC funding, achieved early industry validation like partnerships (e.g., Symeres), and is backed by Y Combinator.[2][4][6]
Yoneda Labs was founded in 2023 by a team of University of Cambridge graduates with expertise in chemistry, computer science, robotics, and machine learning, advised by Prof. Scott E. Denmark, a leader in organic chemistry.[1][3][4] Key founder Jan Oboril, who ranked top 11 in the International Chemistry Olympiad for three years, drew inspiration from his time at a major pharmaceutical company, where he spent hundreds of hours on lab trials that he believed could be replaced by machine learning simulations.[3][4] The team, with prior experience at Bayer, Berkeley AI Research, Jane Street, Optiver, and Cisco, emerged from Y Combinator and quickly validated their app through feasibility studies on datasets covering popular organic reactions.[2][4]
Yoneda Labs rides the wave of AI foundation models expanding from language and vision into scientific domains like chemistry, where data scarcity and irreproducibility hinder progress.[1][4] Timing aligns with surging demand for accelerated drug discovery amid pharmaceutical R&D costs exceeding $2B per drug and environmental pressures for greener synthesis.[1] Market forces favoring them include AI's maturation for small-molecule optimization, growing chemoinformatics datasets, and industry adoption of ML (e.g., via partnerships), positioning them to influence pharma and materials sectors by standardizing reaction optimization.[1][3][6] As a Y Combinator graduate, they amplify the startup ecosystem's push into AI-for-science, potentially unlocking faster commercialization of life-saving compounds.[2][4]
Yoneda Labs is primed to scale its foundation model with expanded datasets and enterprise integrations, targeting broader reaction coverage and pharma pilots beyond early wins like Symeres.[1][4][6] Trends like multimodal AI (integrating robotics data) and regulatory pushes for sustainable chemistry will propel growth, evolving their influence from lab tools to industry-standard platforms.[1][3] With $4.5M raised and a Mosaic Score reflecting market potential, expect Series A traction by 2026, cementing their role in making chemical manufacturing as efficient as software development.[2] This positions Yoneda Labs as a transformative force, turning AI from hype into lab reality for chemists worldwide.
YonedaLabs has raised $4.0M in total across 1 funding round.
YonedaLabs's investors include Y Combinator.
YonedaLabs has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Seed in April 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2024 | $4.0M Seed | Y Combinator |